Talk:SGLT2 inhibitor

This article could be updated to reference current trials (such as EASE II) which are looking at GLiflozins in Type 1 DIabetes:

https://clinicaltrials.gov/ct2/show/NCT02414958 — Preceding unsigned comment added by 165.225.80.115 (talk) 13:36, 18 March 2016 (UTC)

SGLT2 inhibitors and the heart

doi:10.1161/CIRCULATIONAHA.116.021887 JFW | T@lk 08:22, 7 September 2016 (UTC)

... and heart failure in particular doi:10.1161/CIRCULATIONAHA.117.030012 JFW | T@lk 20:13, 24 October 2017 (UTC)

As dapagliflozin blocks glucose resorption in renal tubules, it induces an increased urine output, with positive glucose in urine dipstick or lab tests. Dapagliflozine has the indication, besides T2DM, of Heart Failure: Could this dapagliflozine beneficial effect on HF come just from its diuretic effect, or is something more? Blessings +

External links modified

Hello fellow Wikipedians,

I have just modified one external link on Gliflozin. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

• Added archive https://web.archive.org/web/20141105201008/http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-01-14-fda-approves-jardiance-empagliflozin-tablets-reduce-blood-sugar-levels-adults-type-2-diabetes.html to http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-01-14-fda-approves-jardiance-empagliflozin-tablets-reduce-blood-sugar-levels-adults-type-2-diabetes.html

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

• If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
• If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 17:29, 18 October 2017 (UTC)

Halogens at the aromatic ring

No, they do not reduce metabolism by their electron affinity. They just block the position where enzymes will place a hydroxy group thus making the substance more soluble for excretion. And electron affinity is of no importance here. What is important here is the electronegativity and the polarizibility of the halogens. --FK1954 (talk) 14:41, 12 April 2019 (UTC)

electron affinity?

What is really meant with electron affinity in this article is the electronegativity. This is the electron-withdrawing force and a very different thing than electron affinity because electronegativity has to do with bonds; electron affinity ONLY with single atoms! --FK1954 (talk) 15:03, 12 April 2019 (UTC)

BMJ

doi:10.1136/bmj.m4147 JFW | T@lk 09:59, 22 November 2020 (UTC)

Mechanism Of Action

The "Work is underway....great promise" sentence needs a citation.

The mechanism of action on a cellular level is not well understood. Work is underway to define this mechanism as a prodiuretic with great promise. However, it has been shown that binding of different sugars to the glucose site affects the orientation of the aglycone in the access vestibule. So when the aglycone binds it affects the entire inhibitor. Together these mechanisms lead to a synergistic interaction. Therefore, variations in the structure of both the sugar and the aglycone are crucial for the pharmacophore of SGLT inhibitors. 71.178.185.35 (talk) 04:38, 11 April 2025 (UTC)

Yes, that sentence not very encylcopedic. Also it belongs in uses. So I moved it and added a ref. Jaredroach (talk) 18:23, 11 April 2025 (UTC)

Brand name

Dapagliflozin Brand name is Farxiga not Forxiga ~2026-23732-49 (talk) 00:29, 18 April 2026 (UTC)

In the US, that's true. But in the EU it is Forxiga: https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga Getwood (talk) 16:25, 19 April 2026 (UTC)

SGLT2 inhibitors may cause erythrocytosis.

These citations may be useful regarding the risk of erythrocytosis …

— Chin-Yee et al (2020) DOI: 10.1503/cmaj.76686

— Chin-Yee et al (2022) DOI: 10.9778/cmajo.20210322

— Gangat et al (2023) DOI: 10.1002/ajh.26933

— Liu et al (2024) DOI: 10.1111/joim.13722 Layzeeboi (talk) 00:30, 9 May 2026 (UTC)